- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07453823
The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals (myBIOM)
The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals: a Randomized, Double-blind, Placebo-controlled Study
The study is a single-center, randomized, double-blind, placebo-controlled study in middle-aged to elderly adults. The study includes an 8-week intervention period followed by a 2-week follow-up period. The study will evaluate the effect of a synbiotic consisting of two probiotic strains and a prebiotic.
The aim is to investigate the effect of the synbiotic on modulating the gut microbiota and improving markers of gastrointestinal permeability and integrity and gastrointestinal discomfort.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Sara Engel, PhD
- Telefonnummer: +45 45 74 74 74
- E-Mail: saen@novonesis.com
Studieren Sie die Kontaktsicherung
- Name: Emma Harrington
- E-Mail: eharrington@atlantiatrials.com
Studienorte
-
-
Blackpool
-
Cork, Blackpool, Irland, T23 R50R
- Rekrutierung
- Atlantia Clinical Trials Ltd
-
Kontakt:
- Emma Harrington
- Telefonnummer: +353 (0)21 430 7442
- E-Mail: eharrington@atlantiatrials.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Be able to give informed consent.
- Be between 45 to 70 years of age (inclusive).
- BMI <40.0 kg/m²
- Willing to maintain current level of physical activity and diet during the participation in the study.
- Experience ≤4 bowel movements per week within the month prior to screening
- Participants reported subclinical mild to moderate gastrointestinal complaints as defined by GSRS-IBS score 20-52 at screening.
- Willing to consume the study product daily for the duration of the study.
- Willing to eat the same meal the evening before visiting site (visit 2 to visit 5).
Participants are eligible for randomization if they fulfill the following two criteria based on the diary recordings during the run-in period prior to visit 2 9. Average GSRS-IBS composite symptom score between 20-52 during the two-week run-in period Record ≤8 bowel movements in the daily diary during the two-week run-in period
Exclusion Criteria:
-
Has a history of drug and/or alcohol abuse.
-
Has food allergies, or other issues with foods, that would preclude intake of the study products.
-
Smoking, chewable tobacco and/or vaping and/or use of other nicotine products.
-
Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include:
- diagnosis of GI disease (e.g. gastric or duodenal ulcers, inflammatory bowel disease, colon cancer) or irritable bowel syndrome (IBS)
- GI surgery that might have an effect on gastrointestinal tract function except cholecystectomy and appendectomy in the past 5 years or any major bowel resection at any time.
- history of CVD
- uncontrolled hypertension
-
Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:
- systemic antimicrobial medication (including suppositories) within 4 weeks prior to visit 1
- OTC medications, for digestive symptoms such as PPIs, anti-spasmodics, laxatives, anti-diarrheic drugs within 2 weeks prior to visit 1
10. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.
11. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.
c. immunosuppressant drugs within the 4 weeks prior to the visit 1 d. systemic steroids within the 4 weeks prior to the visit 1 6. Regular oral non-steroidal anti-inflammatory (NSAIDs) within 1 week prior to visit 1 (topical NSAIDS allowed, Low-dose prophylactic aspirin use is acceptable if stable for 3 months prior to screening.) 7. Current or recent (in the past 4 weeks prior to visit 1) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results, including:
a. Herbal supplements for digestive symptoms b. Large doses of vitamins and minerals, unless in stable dose c. Probiotic supplements d. Iron supplements 8. Current or recent (in the past 2-weeks) use of prohibited foods including yoghurts containing probiotics.
9. Planned major changes in lifestyle [i.e., diet (e.g. start of fibre-enriched diet), dieting, exercise level, travelling] during the duration of the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Synbiotic
Synbiotic dietary supplement |
Synbiotic - Given daily for 56 days |
|
Placebo-Komparator: Placebo
Identical looking placebo consisting of maltodextrin |
Placebo - Given daily for 56 days |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Bifidobacterium abundance
Zeitfenster: From baseline to end of intervention at 8 weeks
|
Change in total relative abundance of Bifidobacterium from baseline to 8 weeks assessed from fecal samples. Abundance is calculated based on shotgun metagenomic sequencing. |
From baseline to end of intervention at 8 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Stool frequency
Zeitfenster: From baseline to end of intervention at 8 weeks
|
Change in number of daily bowel movements from 2 weeks average prior to baseline to 2 weeks average prior to end of intervention. An increase is desirable. |
From baseline to end of intervention at 8 weeks
|
|
Fecal acetate
Zeitfenster: From baseline to end of intervention at 8 weeks.
|
Change in fecal acetate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks. |
From baseline to end of intervention at 8 weeks.
|
|
Fecal propionate
Zeitfenster: From baseline to end of intervention at 8 weeks.
|
Change in fecal propionate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks. |
From baseline to end of intervention at 8 weeks.
|
|
Fecal butyrate
Zeitfenster: From baseline to end of intervention at 8 weeks
|
Change in fecal butyrate as measured by targeted metabolomics (GC-MSMS) from baseline to 8 weeks. |
From baseline to end of intervention at 8 weeks
|
|
Zonulin
Zeitfenster: From baseline to end of intervention at 8 weeks
|
Change in serum zonulin from baseline to 8 weeks |
From baseline to end of intervention at 8 weeks
|
|
Lipopolysaccharide binding protein (LPS-BP)
Zeitfenster: From baseline to end of intervention at 8 weeks
|
Change in plasma LPS-BP from baseline to 8 weeks |
From baseline to end of intervention at 8 weeks
|
|
Interleukin 6 (IL-6)
Zeitfenster: From baseline to end of intervention at 8 weeks
|
Change in serum IL-6 from baseline to 8 weeks |
From baseline to end of intervention at 8 weeks
|
|
High-sensitivity C-Reactive Protein (hsCRP)
Zeitfenster: From baseline to end of intervention at 8 weeks
|
Change in serum hsCRP from baseline to 8 weeks. |
From baseline to end of intervention at 8 weeks
|
|
Fecal Short-Chain Fatty Acids (SCFA)
Zeitfenster: From baseline to end of intervention at 8 weeks
|
Change in composite measurement of fecal SCFAs panel with targeted metabolomics (GC-MSMS) from baseline to 8 weeks. Total composite is defined as: acetate + propionate + butyrate. |
From baseline to end of intervention at 8 weeks
|
|
Stool consistency
Zeitfenster: From baseline to end of intervention at 8 weeks
|
Change in mean stool consistency assessed daily from 2 weeks prior to baseline to daily 2 weeks prior to end-of intervention. Stool consistency will be assessed by Bristol stool chart scale rated Type 1 (separate hard lumps) to Type 7 (watery, no solid pieces). An increase in stool consistency is desirable. |
From baseline to end of intervention at 8 weeks
|
|
Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) score
Zeitfenster: From baseline to end of intervention at 8 weeks
|
Change in GSRS-IBS composite score from baseline to end-of-intervention visit. The GSRS-IBS questionnaire includes 13 items that measure the severity of IBS symptoms in five clusters (pain, bloating, constipation, diarrhea and early satiety) during the last seven days. A decrease is desirable. |
From baseline to end of intervention at 8 weeks
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Recovery of probiotic strains
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Recovery and colonization of strains by strain specific qPCR of fecal samples |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
Total relative abundance of Bifidobacterium
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up.
|
Change in total relative abundance of Bifidobacterium after 2 weeks of follow-up (no intervention) compared to effect after 3 weeks and 8 weeks of intervention. |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up.
|
|
Microbiome composition and taxonomic profiles
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Changes in gut microbiome composition and taxonomic profiling analyzed by shotgun metagenomic sequencing of fecal samples |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
Microbiome functional profiling
Zeitfenster: Basline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Change in gut microbiome functional profiling analyzed by shotgun metagenomic sequencing of fecal samples |
Basline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
Plasma Metabolomics
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Change in blood metabolome as assessed by untargeted and targeted metabolomics from plasma samples |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
Fecal metabolomics
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Change in fecal metabolome as assessed by untargeted and targeted metabolomics from fecal samples |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
Bacterial HMO utilization genes
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Abundance development over time of HMO degradation and modification genes such as Glycosyl hydrolases, encoded by probiotic supplements and endogenous gut species |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
HMO concentration in blood and feces
Zeitfenster: Baseline, 3 weeks and end of intervention at 8 weeks
|
Change in HMO in plasma and fecal samples after 3 and 8 weeks of supplementation |
Baseline, 3 weeks and end of intervention at 8 weeks
|
|
Fecal pH
Zeitfenster: Baseline, 3 weeks and end of intervention at 8 weeks
|
Change in pH assessed using a pH meter in fecal samples |
Baseline, 3 weeks and end of intervention at 8 weeks
|
|
Inflammatory Biomarkers
Zeitfenster: Baseline, 3 weeks and end of intervention at 8 weeks
|
Change in inflammatory biomarkers measured in serum |
Baseline, 3 weeks and end of intervention at 8 weeks
|
|
Cardiometabolic Biomarkers
Zeitfenster: Baseline, 3 weeks and end of intervention at 8 weeks
|
Change in cardiometabolic biomarkers |
Baseline, 3 weeks and end of intervention at 8 weeks
|
|
Cognitive function measured by the Trails Making Test (Parts A & B)
Zeitfenster: Baseline and end of intervention at 8 weeks
|
Change in cognitive function assessed using Trail Making Test (Parts A & B) |
Baseline and end of intervention at 8 weeks
|
|
Cognitive function measured by the Stroop Colour and Word Test
Zeitfenster: Baseline and end of intervention at 8 weeks
|
Change in cognitive function assessed using the Stroop Colour and Word Test |
Baseline and end of intervention at 8 weeks
|
|
Cognitive function measured by the Symbol Digit Modalities Test (SDMT)
Zeitfenster: Baseline and end of intervention at 8 weeks
|
Change in cognitive function assessed using the Symbol Digit Modalities Test (SDMT) |
Baseline and end of intervention at 8 weeks
|
|
Health-related Quality of Life
Zeitfenster: Baseline, 3 weeks and end of intervention at 8 weeks
|
Change in health-related quality of life assessed by Short Form-36 (RAND SF-36) |
Baseline, 3 weeks and end of intervention at 8 weeks
|
|
Gastrointestinal Symptoms Measured by the GSRS-IBS Total Score
Zeitfenster: Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
Change in gastrointestinal symptoms by assessing the Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS). The outcome reflects the total composite score. A decrease is desirable. |
Baseline, 3 weeks, 8 weeks (end of intervention) and 2 weeks of follow-up
|
|
GSRS-IBS Pain Subscale
Zeitfenster: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up.
|
Change in the gastrointestinal symptom pain assessed using GSRS-IBS subscale for Pain. A decrease is desirable. |
Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up.
|
|
GSRS-IBS Bloating Subscale
Zeitfenster: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
Change in the gastrointestinal symptom bloating assessed using GSRS-IBS subscale for bloating. A decrease is desirable. |
Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
|
GSRS-IBS Constipation Subscale
Zeitfenster: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
Change in the gastrointestinal symptom constipation assessed using GSRS-IBS subscale for constipation. A decrease is desirable |
Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
|
GSRS-IBS Diarrhea Subscale
Zeitfenster: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
Change in the gastrointestinal symptom Diarrhea assessed using GSRS-IBS subscale for Diarrhea. A decrease is desirable. |
Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
|
GSRS-IBS Early Satiety Subscale
Zeitfenster: Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
Change in the gastrointestinal symptom early satiety assessed using GSRS-IBS subscale for early satiety. |
Baseline, 3 weeks, 8 weeks, and 2 weeks of follow-up
|
|
Protein Composite Score
Zeitfenster: Baseline, 3 weeks and end of intervention at 8 weeks
|
Change in protein composite score measured using OLINK Reveal panel |
Baseline, 3 weeks and end of intervention at 8 weeks
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Martin Buckley, Professor, Atlantia Clinical Trials Ltd
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- HHB-GI-2406
- ECM4(i)11/12/2025 (Andere Kennung: Clinical Research Ethics Committee of the Cork Teaching Hospitals)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .